115
Views
12
CrossRef citations to date
0
Altmetric
Drug Evaluation

Vinorelbine in breast cancer

&
Pages 2901-2910 | Published online: 20 Oct 2008
 

Abstract

Vinorelbine is a semi-synthetic vinca-alkaloid that has been approved in the treatment of advanced breast cancer. Two pharmaceutical forms, intravenous and oral, have been developed and the dose equivalence has been demonstrated to be between 30 mg intravenous and 80 mg oral. Efficacy is similar and tolerability is good in both forms, with more frequent nausea and vomiting with oral vinorelbine. Both induce neutropenia. Vinorelbine can be combined with anthracyclines and taxanes – the main toxicity being neutropenia. It can be used alone or in combination, particularly with capecitabine, in patients previously treated with anthracyclines and taxanes. A synergistic effect has been observed between vinorelbine and trastuzumab in patients with a hyperexpression of HER2 in their tumours.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.